eravacycline dihydrochloride · Tetraphase Pharms · NDA 211109
Xerava
Earliest generic entry, as listed · earliest of 2 marketed strengths
19 Oct 2037
Blocked by patent: US 10961190, US 11578044.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10961190 | substance | 19 Oct 2037 |
| US 11578044 | substance | 19 Oct 2037 |
| US 8906887 | product | 27 Aug 2032 |
| US 8796245 | use U-2380 | 7 Aug 2029 |
Exclusivities · 1 unexpired
| GAIN | qualified infectious disease product | 27 Aug 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211109 · 001 · RLD | powder, intravenous | EQ 50MG BASE/VIAL | 19 Oct 2037 |
| 211109 · 002 · RLD | powder, intravenous | EQ 100MG BASE/VIAL | 19 Oct 2037 |
Expired or delisted (1)
- NCE · 27 Aug 2023